RESPONSE UNDER 37 CFR 1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1623

CCD Q 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/290

In re the application of:

DE FLORA, et al.

Serial Number: 09/125,022

Filed: November 24, 1998

Group Art Unit: 1623

Examiner: G. Kunz

For: PHARMACEUTICAL COMPOSITION ENABLING TO INHIBIT CANCER

METASTASIS FORMATION CONTAINING N-ACETYL-CYSTEINE AND

DOXORUBICIN

RESPONSE UNDER 37 CFR 1.116

Assistant Commissioner for Patents **Box AF**Washington, D.C. 20231

February 4, 2000

Sir:

In response to the Office Action dated August 4, 1999, a Petition for Extension of Time for three months from November 4, 1999 to February 4, 2000 attached hereto, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 10-12 without prejudice or disclaimer, and add the following new claims.

olf.